Fluvastatin improves pro-inflammatory and pro-thrombotic markers in aPL-positive patients
As reported in the Annals of Rheumatic Diseases, treatment of persistent aPL-positive patients with fluvastatin (40 mg qd x 3 months) improved pro-inflammatory and pro-thrombotic markers (IL1-β, VEGF, TNF-α, IP10, sCD40L, and sTF).
Metacarpal DXR-BMD predicts 1-y RA progression
As reported in the Annals of Rheumatic Diseases, a metacarpal BMD determination after 4 months of anti-RA treatment is an independent predictor of 1-y progression in patients without baseline bone erosions (OR=2.0). For patients with baseline erosions, early metacarpal BMD loss is predictive of 1-y progression (OR=1.5).
Low vitamin D associated with statin-induced myalgia
As reported in Clinical Therapeutics, of 450 patients prescribed high-dose simvastatin (80 mg qd) for dyslipidemia, 11.1% complained of myalgias. The vitamin D level was lower in patients with myalgias than patients without myalgias (26.2 vs. 36.3 ng/mL).